title: [Prospective, multicentric, open, and controlled evaluation of the effectiveness of prostatron 2.5 in the treatment of prostatic benign hypertrophy: 1-year results].
abstract: OBJECTIVE
  Evaluation of the efficacy at 1 year of the Prostatron 2.5 in the treatment of BPH weighing more than 40 grams.
  
  
  METHODS
  46 patients over the age of 50 years presenting with BPH > 40 grams responsible for a maximum flow rate (MFR) < 9 ml/s and a mean IPSS score of 18 were prospectively included without randomization, by 5 French Urological Centres. These patients were reviewed at 3, 6 and 12 months. Primary endpoint: MFR; secondary endpoints: Madsen score and IPSS.
  
  
  RESULTS
  No major complications were observed. The mean postoperative catheterization time was 10 days, causing discomfort with a mean score of 5 on a visual analogue scale from 0 to 10.. Maximum flow rate waas 13.4 ML/s at 3 months, 13.4 ml/s at 6 months and 14.7 ml/s at 12 months. The IPSS was improved by 75%.
  
  
  CONCLUSIONS
  Treatment by Prostatron 2.5 improves the MFR and the patient's quality of life, which is maintained for at least 1 year after treatment.
authors.affiliation: Service d'Urologie, Hôpital Tenon, Paris, France. bernard.gattegno@tnn.ap-hop-paris.fr
authors.forename: B
authors.initials: B
authors.lastname: Gattegno
authors.forename: C
authors.initials: C
authors.lastname: Ciofu
authors.forename: A
authors.initials: A
authors.lastname: Flahaut
authors.forename: E
authors.initials: E
authors.lastname: Chartier-Kastler
authors.forename: F
authors.initials: F
authors.lastname: Desgrandchamps
authors.forename: X
authors.initials: X
authors.lastname: Martin
authors.forename: G
authors.initials: G
authors.lastname: Vallancien
authors.forename: P
authors.initials: P
authors.lastname: Teillac
authors.forename: F
authors.initials: F
authors.lastname: Richard
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000628:therapy*; D013997:Time Factors
vernacular_title: Evaluation prospective, multicentrique, ouverte et contrôlée de l'efficacité du Prostatron 2.5 dans le traitement de l'hypertrophie bénigne de la prostate: résultats à 1 an.